🧬 CJC‑1295 (No DAC) + Ipamorelin Peptide Blend

Dual‑Pathway GHRH & GHSR‑1a Research Peptides for Endocrine Signaling & Receptor‑Pathway Studies (Canada)

CJC‑1295 (No DAC) + Ipamorelin is a high‑purity, research‑grade dual‑peptide formulation widely referenced in laboratory research involving endocrine signaling, receptor co‑activation, intracellular messenger integration, and peptide‑receptor kinetics.

Supplied by BlueNexLabs, this formulation combines CJC‑1295 (No DAC)—a short‑acting GHRH analog—with Ipamorelin, a selective GHSR‑1a agonist. Together, they support controlled investigation of parallel receptor systems under Research‑Use‑Only (RUO) conditions in Canadian research environments.

🔬 Overview of the CJC‑1295 (No DAC) + Ipamorelin Research Model

This dual‑peptide system is commonly used as a model platform for studying how GHRH receptor (GHRH‑R) signaling and growth hormone secretagogue receptor (GHSR‑1a) signaling behave independently and in combination.

Unlike DAC‑modified peptides, CJC‑1295 (No DAC) lacks a drug‑affinity complex, resulting in short‑window receptor engagement. This property makes it particularly useful for high‑resolution kinetic studies and time‑course experiments focused on pulsatile receptor activation patterns.

When paired with Ipamorelin, researchers can explore dual‑pathway signaling architecture without long‑acting peptide confounders.

🧪 What Is CJC‑1295 (No DAC) + Ipamorelin?

This formulation contains two distinct research peptides:

CJC‑1295 (No DAC)

• Synthetic GHRH analog without DAC modification

• Used in laboratory models of GHRH‑R binding and cAMP‑linked signaling

• Short in‑vitro half‑life supports temporal resolution studies

Ipamorelin

• Selective GHSR‑1a pentapeptide agonist

• Used in studies of Ca²⁺ mobilization and receptor‑bias behavior

• Demonstrates predictable, receptor‑specific signaling in vitro

Together, this combination enables dual‑axis endocrine signaling research under controlled laboratory conditions.

📡 Mechanistic Research Overview (Audit‑Safe)

🧬 Dual‑Receptor Pathway Activation

• Used to study simultaneous GHRH‑R and GHSR‑1a engagement

• Supports analysis of receptor crosstalk and pathway amplification

• Applied in comparative single‑ vs. dual‑receptor studies

⚙️ Intracellular Messenger Integration

• Referenced in research examining cAMP signaling (GHRH‑R)

• Supports studies of Ca²⁺ mobilization (GHSR‑1a)

• Enables mapping of convergent vs. divergent transcriptional responses

🔁 Receptor Bias & Kinetic Behavior

• Applied in assays measuring β‑arrestin recruitment and receptor internalization

• Used for receptor recycling and ligand‑dependent trafficking studies

• Supports short‑window kinetic modeling due to No‑DAC design

🧱 Molecular & Chemical Characteristics

Type: Dual‑peptide research formulation
Form: Lyophilized powder
Fill Size:

• 5 mg CJC‑1295 (No DAC)

• 5 mg Ipamorelin

Identity Verification:

• Each peptide independently verified via Mass Spectrometry (MS)

• Purity confirmed by HPLC / UPLC

Structural & Biochemical Notes

CJC‑1295 (No DAC):

• Short‑acting GHRH analog without albumin‑binding modification

• High solubility in polar buffers

• Stability influenced by pH, ionic strength, and temperature

Ipamorelin:

• Selective GHSR‑1a agonist with low off‑target activity in vitro

• Predictable solubility and low nonspecific binding

• Stability improves in mildly acidic buffer systems

Combined Behavior:

• Supports dual‑axis signaling analysis (cAMP, Ca²⁺, MAPK, CREB)

• Low aggregation risk when properly buffered

• Suitable for time‑course and receptor‑bias experiments

🔬 Research Focus Areas

This dual‑peptide formulation is commonly referenced in research involving:

• Endocrine‑axis and receptor‑coactivation modeling

• GHRH‑R and GHSR‑1a signaling comparison studies

• Intracellular second‑messenger integration

• Receptor‑bias and internalization kinetics

• Peptide–peptide interaction and solubility analysis

• Analytical method development for multi‑peptide systems

Its short‑acting design supports controlled, high‑resolution research workflows.

❄️ Storage & Handling Guidelines

Lyophilized (Unreconstituted)

• Store at –20 °C, protected from light and moisture

• Allow vial to reach room temperature before opening

• Peptides are hygroscopic — minimize humidity exposure

Reconstituted

• Store at 2–8 °C for short‑term research use only

• Prepare minimal working volumes

• Use sterile, low‑binding labware

• Avoid repeated vial punctures

General Handling

• Avoid repeated freeze–thaw cycles; aliquot if needed

• Use appropriate buffer systems to maintain stability

• Minimize oxygen exposure during preparation

📄 Certificate of Analysis & Documentation

Each batch supplied by BlueNexLabs includes audit‑ready documentation, ensuring traceability and reproducibility:

• MS identity confirmation (each peptide)

• HPLC / UPLC purity profiles

• Solvent system disclosure

• Lot and batch traceability

• Research‑Use‑Only (RUO) designation

🔗 View Certificate of Analysis (COA)
🔗 Learn About Our Testing Standards
🔗 Explore the BlueNexLabs Research Peptide Catalog

🇨🇦 Supplied for Canadian Research Laboratories

BlueNexLabs supplies CJC‑1295 (No DAC) + Ipamorelin research peptides to laboratories across Vancouver, Toronto, Montreal, Calgary, Edmonton, Ottawa, and throughout Canada.

Why Researchers Choose BlueNexLabs

• 🇨🇦 Canada‑wide domestic shipping

• 📄 COA‑verified, traceable batches

• 🧪 Audit‑safe RUO labeling

• ⚡ Fast fulfillment & responsive support

• 🔬 Research‑focused endocrine‑pathway peptide catalog

⚠️ Compliance Notice

This product is supplied strictly for laboratory research use only (RUO).
Not for human or veterinary use.
No medical, therapeutic, cosmetic, diagnostic, or performance‑related claims are made or implied.